GlassScriptPhysician profile
Marcella Rowley
NPI 1740301837
$13,498.32
in general payments reported to CMS, 2019-2025
61 companies · $3,805 in 2025
The $3,805 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,881 · 2022: $2,498 · 2023: $2,397 · 2024: $2,917 · 2025: $3,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,620 · Consulting Fee: $350 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,619.67 |
| Consulting Fee | $350.00 |
| Education | $149.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,834.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,515.15 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $1,036.79 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Jazz Pharmaceuticals INC. | $1,031.34 | 2021-2025 | |
| Amgen INC. | $869.16 | 2023-2025 | Repatha, Repatha, Otezla |
| Axsome Therapeutics, INC. | $703.95 | 2022-2025 | Sunosi, Auvelity, Symbravo |
| Novo Nordisk INC | $634.25 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $563.78 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $427.41 | 2024-2025 | Lumryz |
| Corcept Therapeutics | $414.92 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $399.97 | 2021-2025 | Verquvo, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $317.20 | 2022-2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $304.22 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.68 | 2021-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $255.84 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Rowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.